Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

A crystalline compound of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one or a salt thereof.

A crystalline compound of a hydrate of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one or a salt thereof.

A crystalline compound of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one, which has an X-ray powder diffraction analysis pattern with peaks at diffraction angle:)2θ(°) of 4.64, 5.46, 8.40, 11.10, 12.60, 13.10, 14.14, 14.36, 14.60, 15.58, 15.86, 16.24, 16.86, 17.52, 19.26, 19.72, 20.00, 20.40, 20.80, 21.12, 21.70.

A crystalline compound of a hydrate of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one potassium salt, which has an X-ray powder diffraction analysis pattern with peaks at diffraction angle:

• 2θ(°) of 4.46, 6.32, 12.66, 12.84, 13.46, 13.74, 16.82, 17.08, 17.82, 17.98, 18.38, 19.70, 20.34, 21.80, 22.18, 22.80, 24.08, 25.40, 26.70.

A crystalline compound of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one potassium salt.

A crystalline compound of a hydrate of 3-(4-isopropoxyphenyl)-2-methyl-5-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-6-propylpyrimidin-4(3H)-one potassium salt.